BioSpace News Archive

CorWave raised 61 million euros to fund its first industrial deployment and entry into clinical trials.

Catalyst Pharmaceuticals, Inc. announced that Catalyst has entered into a definitive agreement with Santhera Pharmaceuticals Holding under which Catalyst will enter into an exclusive North America license, manufacturing and supply agreement for Santhera’s investigational product candidate, vamorolone, a dissociative steroid currently under FDA review for the treatment of Duchenne Muscular Dystrophy.

Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE.

Merck, known as MSD outside of the United States and Canada, announced topline results from the Phase 3 KEYNOTE-585 trial, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as neoadjuvant treatment, followed by adjuvant treatment with KEYTRUDA plus chemotherapy, then KEYTRUDA monotherapy in patients with locally advanced resectable gastric and gastroesophageal junction adenocarcinoma.

NovaBay® Pharmaceuticals, Inc. announces that it will showcase its Avenova®-branded eyecare products at the 126th Annual American Optometric Association Congress & 55th Annual American Optometric Student Association Conference: Optometry’s Meeting® being held June 21-24, 2023 at the Walter E.

CSL Behring today announced that the first patient has received U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb) for hemophilia B in the United States.

Pathnostics, a leading precision diagnostic testing and development company, today announced the publication of two new studies demonstrating positive outcomes resulting from its advanced urinary tract infection (UTI) test.

Vizgen today announced publication of a study in the June issue of Nature Medicine conducted by Drs. Assaf Magen and Pauline Hamon in the Miriam Merad lab at the Icahn School of Medicine at Mount Sinai, in collaboration with Regeneron Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics (PK) of orally administered single ascending doses (SAD) and multiple ascending doses (MAD) of EDP-323 in healthy adult subjects.

New toolkit to standardize guidelines for streamlined IRB/Ethics review of DCT applications